The FDA has approved a drug called Enhertu (fam-trastuzumab deruxtecan-nxki) for several types of cancer that have a specific protein called HER2. This includes certain breast cancers, lung cancers, stomach cancers, and other solid tumors. Enhertu is a targeted therapy that attacks cancer cells with high levels of HER2. It is given as an infusion into a vein.
For breast cancer, Enhertu is approved as a first treatment along with another drug for HER2 positive cancer that has spread. It is also approved for HER2 low and HER2 ultralow breast cancer after hormone therapy or chemotherapy. For lung cancer, it is for HER2 mutant cancer after other treatments. For other solid tumors, it is for HER2 positive tumors when no other good options exist. For stomach cancer, it is for HER2 positive cancer after a previous treatment.
This approval means more treatment choices for people with these cancers. Enhertu has shown promise in shrinking tumors and delaying cancer growth. However, it can have serious side effects, such as lung problems and heart damage. Patients should talk to their doctor to see if Enhertu is right for them.
If you or a loved one has a HER2 driven cancer, ask your doctor about Enhertu. It is not a cure, but it may be a helpful option. Your doctor can explain the benefits and risks based on your specific situation.